These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8839116)

  • 21. [Estrogen treatment for prevention and therapy of osteoporosis].
    von Werder K
    Fortschr Med; 1997 Oct; 115(29):44-9. PubMed ID: 9445834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results.
    Watts NB
    J Reprod Med; 2002 Jan; 47(1 Suppl):82-92. PubMed ID: 11829081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Osteoporosis from the gynecologic viewpoint].
    Schneider HP; Dören M
    Gynakologe; 1993 Apr; 26(2):83-92. PubMed ID: 8508989
    [No Abstract]   [Full Text] [Related]  

  • 24. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.
    Morishige K; Yamamoto T; Sawada K; Ohmichi M; Tasaka K; Murata Y
    Arch Gynecol Obstet; 2003 Jun; 268(2):105-6. PubMed ID: 12768299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New, pioneering PTH treatment of postmenopausal osteoporosis. Quick effect on bone density and bone formation].
    Törring O
    Lakartidningen; 2001 Oct; 98(42):4552-3. PubMed ID: 11715225
    [No Abstract]   [Full Text] [Related]  

  • 26. Alendronic acid in primary prevention: new indication. No reduction in fracture risk.
    Prescrire Int; 2000 Jun; 9(47):70-2. PubMed ID: 11010741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medications for postmenopausal osteoporosis prevention.
    Harv Womens Health Watch; 2002 Dec; 10(4):6-7. PubMed ID: 12499127
    [No Abstract]   [Full Text] [Related]  

  • 28. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raloxifene therapy in the reduction of fractures.
    Cefalu CA
    Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
    [No Abstract]   [Full Text] [Related]  

  • 30. [Osteoporosis therapy in general practice. Which measure should be included?].
    Abendroth K
    MMW Fortschr Med; 2002 Oct; 144(42):62. PubMed ID: 12534001
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapeutic strategies for osteoporosis].
    Chapurlat R; Delmas PD
    Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoporosis: new hope for the future.
    Masi L; Bilezikian JP
    Int J Fertil Womens Med; 1997; 42(4):245-54. PubMed ID: 9309458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical inquiries. What is the best approach to prevention and treatment of osteoporosis?
    Schwartz K; Chang SI
    J Fam Pract; 2001 Dec; 50(12):1024-5. PubMed ID: 11742601
    [No Abstract]   [Full Text] [Related]  

  • 35. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alendronate in the treatment of osteoporosis.
    Adami S
    Aging (Milano); 1998 Apr; 10(2):159-60. PubMed ID: 9666215
    [No Abstract]   [Full Text] [Related]  

  • 37. Effective strategies to identify postmenopausal women at risk for osteoporosis.
    Levine JP
    Geriatrics; 2007 Nov; 62(11):22-30. PubMed ID: 17999567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic prevention of osteoporotic fractures.
    Zizic TM
    Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention and treatment of osteoporosis: where are we today?
    Maby JI
    J Am Osteopath Assoc; 2003 Feb; 103(2 Suppl 2):S9-12. PubMed ID: 12625633
    [No Abstract]   [Full Text] [Related]  

  • 40. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Gennari L
    Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.